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Abstract Novel antioxidant and anti-inflammatory peptides were isolated from hydrolysates of Siamese 31 
crocodile (Crocodylus siamensis) hemoglobin. Crocodylus siamensis hemoglobin hydrolysates (CHHs) were 32 
obtained by pepsin digestion at different incubation times (2, 4, 6 and 8 H) at 37 C and subjected to antioxidant 33 
and anti-inflammatory activity assessment. CHH obtained by 2-H hydrolysis (2H-CHH) showed the highest 34 
anti-inflammatory activity with respect to decreasing nitric oxide (NO) production, while the strongest 35 
antioxidant activity was found for 6-H hydrolysis (6H-CHH) against nitric oxide radicals. To evaluate the anti-36 
inflammatory and antioxidant activity of individual peptide components, 2H-CHH and 6H-CHH were purified 37 
by semi-preparative HPLC. Peptide fraction P57 isolated from 6H-CHH was found to exhibit the highest nitric 38 
oxide radical inhibition activity (32.0%). Moreover, purification of 2H-CHH yielded peptide fraction P16, 39 
which displayed a high efficacy in decreasing NO production of macrophage RAW 264.7 cells (83.2%) and 40 
significantly reduced pro-inflammatory cytokines and inflammatory mediators interleukin-6 (IL-6), interleukin-41 
1 beta (IL-1β) and prostaglandin-E2 (PGE2) production to about 2.0, 0.3 and 1.9 ng/mL, respectively. Using 42 
LTQ orbitrap XL mass spectrometry, active peptide sequences were identified as antioxidant KIYFPHF (KF7), 43 
anti-inflammatory SAFNPHEKQ (SQ9) and IIHNEKVQAHGKKVL (IL15). Additionally, CHHs simulated 44 
gastric and intestinal in vitro digestion positively contributed to antioxidant and anti-inflammatory activity. 45 
Taken collectively, the results of this work demonstrate that CHHs contain several peptides with anti-46 
inflammatory and antioxidant properties which may prove valuable as treatment or supplement against diseases 47 
associated with inflammation and oxidative stress. 48 
 49 
Keywords: Crocodylus siamensis, enzymatic hydrolysis, hemoglobin hydrolysate, inflammation, oxidative stress, 50 
purification and identification 51 
 52 
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1. Introduction 61 
Inflammation, oxidative stress and free radical damage have recently been acknowledged as a global threat for 62 
human health. Albeit being common by-products of a broad range of processes ensuring cellular homeostasis, 63 
excessive generation of radical metabolites is unambiguously associated with a variety of serious disorders such 64 
as cancer, heart disease, strokes, Alzheimer’s, and premature aging [1]. Similarly, the inflammatory response 65 
constitutes an important natural reaction of the host defense system to injury and the invasion of toxins or 66 
infectious particles. In the case of pathogenic infection, inflammation contributes to combatting the disease and 67 
protecting vital parts of the body, while suspending the normal immune response and shunting certain metabolic 68 
pathways at the same time. Specific pro-inflammatory mediators and cytokines, such as NO, PGE2, TNF-α, IL-69 
1β and IL-6, comprise vital parts of the inflammatory cascade and are generated to affect immune cell function 70 
as well as proliferation activity [2]. In the long term, however, inflammatory processes are known to result in 71 
progressive damage and are usually associated with excessive free radical release and oxidative stress [3]. 72 
The latter is defined as an inequality between the free radicals production and reactive metabolites resulting 73 
in damage to cells and important biomolecules which severely impacts all organisms [4]. Free radicals, which 74 
account for the majority of both reactive nitrogen species (RNS) and reactive oxygen species (ROS), are defined 75 
as molecular species possessing one or more non-bonding paired electrons in spatially different orbitals of atoms 76 
or molecules [5]. Also, they have high potential to either donate an electron to or accept an electron from other 77 
molecules, consequently behaving as oxidants [6]. The latter process is capable of inflicting severe damage to 78 
the membranes and nuclei of cells by oxidizing important biochemical molecules such as proteins, lipids, 79 
carbohydrates, and DNA [7]. During the course of the inflammation high amounts of free radicals are produced 80 
within the inflamed tissue, in particular NO, which acts as a major pro-inflammatory mediator in the human 81 
body and is generated from macrophage in response to the inflammation [8]. In this context NO is generally 82 
regarded as the key mediator correlating inflammation and oxidative stress. The discovery and development of 83 
substances capable of inhibiting either the activity or production of NO has therefore gained considerable 84 
attention within the recent years as they may be utilized to reduce the detrimental effects of both inflammation 85 
and oxidative damage. 86 
Crocodylus siamensis, commonly called Siamese crocodile, is a small freshwater crocodilian populating 87 
parts of Southeast Asia, including Thailand. Recently, several components of C. siamensis blood, i.e. plasma, 88 
serum, white blood cells and hemoglobin have been reported to possess a broad spectrum of biological 89 
properties, mainly attributed to abundance of a number of biologically active peptides and proteins. Among 90 
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these, hemoglobin constitutes the most abundant component and has been shown to exhibit antimicrobial [9], 91 
antioxidant [10, 11] and anti-inflammatory activity [11, 12].   92 
In addition to the direct extraction of specific proteins with desired biological activity, enzymatic hydrolysis 93 
of protein sources has been established as a convenient method to generate novel protein fragments with 94 
enhanced biological properties. A variety of animal proteins was shown to be applicable for producing bioactive 95 
peptides via protein hydrolysis within recent decades, granting access with specific properties of interest such as 96 
inhibitory activity on angiotensin I converting enzyme [13-16], antibacterial activity [17], antioxidant activity 97 
[18, 19] and anti-inflammatory activity [20]. In this context, it is anticipated that the biological properties of C. 98 
siamensis blood proteins and their potent antioxidant and anti-inflammatory activity may be further enhanced by 99 
protein hydrolysis. 100 
 As a consequence, this study aimed to investigate the antioxidant and anti-inflammatory peptides from C. 101 
siamensis hemoglobin hydrolysates (CHHs) derived by pepsin digestion. NO scavenging, linoleic peroxidation 102 
and ferric reducing power assays were conducted to determine the antioxidant activity of the CHHs, whereas 103 
MTT, NO (of macrophage RAW 264.7 cells), IL-6, IL-1β and PGE2 assays were used to investigate the anti-104 
inflammatory activity. In vitro digestion and hemolytic activity were used to determine the application uses. 105 
Furthermore, the identity of the antioxidant and anti-inflammatory peptides was elucidated via amino acid 106 
sequence determination using ultra-high performance liquid chromatography-LTQ orbitrap XL mass 107 
spectrometry. 108 
 109 
2. Materials and Methods 110 
2.1. Materials and reagents  111 
RPMI 1640 medium, antibiotic/antimycotic (penicillin/streptomycin/amphotericin B), trypsin–EDTA and fetal 112 
bovine serum (FBS) were purchased from Gibco (USA). Pepsin from porcine gastric mucosa, picrylsulfonic 113 
acid solution (TNBS), sodium sulfite, L-leucine, ammonium thiocyanate, ferrous chloride, potassium 114 
hexacyanoferrate, ferric chloride, Linoleic acid, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carbonic acid 115 
(Trolox), glutathione (GSH), 2,20-azobis-(2-amidinopropane)-dihydrochloride (ABAP), dimethyl sulfoxide 116 
(DMSO), lipopolysaccharide (LPS), NaCl, HCl, PBS, bile salts solution, pancreatin solution, CaCl2, Triton X-117 
100 were purchased from Sigma-Aldrich (Germany). Sodium nitroprusside was purchased from Merck 118 
(Germany). 3-(4,5-diamethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Eugene 119 
(USA).  120 
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2.2. Crocodile hemoglobin preparation 121 
Crocodile blood was collected from a slaughterhouse (Srirachamoda Co., Ltd.) in Thailand, and the extraction of 122 
hemoglobin from red blood cells was performed following the method of Srihongthong et al. [9]. Blood was 123 
collected and transferred to 15 mL sterile tubes containing 0.08 g of EDTA. Blood samples were stored at 4 C 124 
overnight to allow blood cells to settle. Red blood cells (bottom layer) were collected in sterile tubes after 125 
elimination of plasma (top layer) and white blood cells (middle layer). Isolated red blood cells were washed 126 
three times with phosphate buffer saline (PBS), pH 7.0, and centrifuged at 3,000g for 5 min at 4 C. Ice-cold 127 
distilled water of five-fold volume was added to the RBC pellet, followed by vigorous mixing and allowing the 128 
mixture to settle for 10 min. After centrifugation at 10,000g for 20 min at 4 C, the supernatant was collected for 129 
lyophilization and then stored at −70 C. 130 
 131 
2.3. Enzymatic hydrolysis 132 
Enzymatic hydrolysis was performed according to the method of Yu et al. [21]. Shortly, the hemoglobin 133 
solution was digested by pepsin with a ratio of enzyme to substrate of 1:100 (w/w) at 37 C for 2, 4, 6 and 8 H 134 
and boiled at 95 C for 10 min to quench the reaction by inactivating the enzyme. The hydrolysis condition of 135 
hemoglobin by pepsin was performed at pH 2.0 (adjusted with 1 M HCl), followed by removal of insoluble 136 
components by centrifugation at 7,168g for 20 min. The supernatant was collected and adjusted to pH 7.0 by 137 
addition of 1 M HCl or 1 M NaOH. Finally, the supernatants of the crocodile hemoglobin hydrolysates (CHHs) 138 
were lyophilized and stored at −20 C. 139 
 140 
2.4. Degree of hydrolysis 141 
The degree of hydrolysis was determined following the method of Benjakul et al. [22]. Briefly, 125 µL of CHHs 142 
were added to 2.0 mL of 0.21 M sodium phosphate buffer, pH 8.2, followed by addition of 1 mL of 0.01% 143 
TNBS solution. The mixture was incubated in a water bath at 50 C for 30 min in the dark, and 2 mL of 0.1 M 144 
sodium sulfite was added to stop the reaction. The mixture was then allowed to cool for 15 min. The absorbance 145 
was measured at 420 nm and the α-amino acid content expressed in terms of L-leucine. The percentage of the 146 
degree hydrolysis was calculated using the formula:  147 
DH = [(Lt – L0)/(Lmax – L0)] × 100 148 
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where L0 determines the amount of α-amino acid expressed in the sample. Lt corresponds to the amount of α-149 
amino acid released at time t. L max determines the maximum amount of α-amino acid after hydrolysis by 5 M 150 
HCl at 100 C for 24 H. 151 
 152 
2.5. Nitric oxide (NO) scavenging assay  153 
Nitric oxide (NO) was generated from sodium nitroprusside and measured using Griess reagent. The assay was 154 
conducted according to the method of Yen et al. [23] with modifications. For the experiment, 250 µL sodium 155 
nitroprusside (10 mM) in PBS were mixed with 15, 31, 62, 125, 250 and 500 µg/mL of CHHs and incubated at 156 
25 C for 2 H. An aliquot of the incubated solution (100 µL) was added to 100 µL of Griess reagent (1% 157 
sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride) and incubated in the 158 
dark for 10 min before measuring the absorbance at 540 nm. Butylated hydroxytoluene (BHT) was used as a 159 
positive control. All samples were analyzed in quadruplicate.The percentage of inhibition was calculated using 160 
the formula:% inhibition = [(Abscont – Abstest)/Abscont] × 100.  161 
 162 
2.6. Linoleic peroxidation assay 163 
This assay was performed following the method of Ledesma et al. [24] with modifications. Briefly, 50 µL of 164 
CHHs (0.005, 0.05, 0.5, 5, 50 and 500 µg/mL) were added to 50 µL of linoleic acid (0.05% v/v) solution. 0.07 165 
M ABAP (10 µL) was added and the solution mixed for 10 min. After addition of 150 µL 20% (v/v) acetic acid, 166 
the mixture was incubated at 70 C for 1 H. Twenty microliter of each solution was then added to a 96-well 167 
plate already containing 75% ethanol (160 µL), 15% ammonium thiocyanate (10 µL) and 10 mM ferrous 168 
chloride (10 µL). The new solution was mixed and incubated at for 3 min. The absorbance was measured at 500 169 
nm and Trolox used as positive control. All samples were analyzed in sextuplicate. The antioxidant activity was 170 
analyzed and the percentage of antioxidant inhibition (% AI) of each sample was calculated using the following 171 
formula:  172 
% AI (antioxidant inhibition) = 100 × [Abscont – Abstest)/Abscont]  173 
 174 
2.7. Ferric reducing power assay 175 
This assay was modified from the method of Girgih et al. [25]. Briefly, 250 µL of CHHs (0.005, 0.05, 0.5, 5, 50 176 
and 500 µg/mL) and positive control (glutathione) were added to 250 µL of 0.2 M phosphate buffer, pH 6.6. 250 177 
µL of 1% (w/v) potassium hexacyanoferrate solution were added, vortexed and the mixture incubated at 50 C 178 
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for 20 min. The reaction was quenched by adding 250 µL of 10% TCA and incubated for 10 min before 179 
centrifugation at 800g for 10 min. Aliquots of each solution (30 µL) were then transferred to a 96-well plate 180 
already containing double distilled water (160 µL) and 0.1% (w/v) ferric chloride (10 µL). The reaction mixture 181 
was homogenized and incubated at 25 C for 10 min, followed by measuring the absorbance at 700 nm. All 182 
samples were analyzed in quadruplicate. The antioxidant activity for each sample was expressed as Trolox 183 
(mM) equivalents and calculated using the equation of the standard curve of the positive control. 184 
 185 
2.8. Cell culture 186 
A murine macrophage cell line (RAW 264.7) was purchased from the American Type Culture Collection 187 
(American Type Culture Collection [ATCC], USA) and cultured in RPMI 1640 medium supplemented with 188 
10% heat-inactivated fetal bovine serum (FBS), 100 µg/mL of streptomycin, 100 U/mL of penicillin, 25 µg/mL 189 
amphotericin B and incubated at 37 C in a 5% CO2 humidified atmosphere. 190 
 191 
2.9. Measurement of nitric oxide 192 
This assay was conducted according to the method of Phosri et al. [11]. CHHs (62, 125, 250 and 500 µg/mL) 193 
were mixed with LPS (100 ng/mL), and the resulting solution incubated with RAW 264.7 cells. Another 194 
incubation was set up between LPS and RAW 264.7 cells at 37 C in a 5% CO2 humidified atmosphere for 24 195 
H. 100 µL of culture medium from each CHH sample were slightly mixed with 100 µL of Griess reagent and 196 
incubated at 25 C for 10 min. The absorbance was measured at 540 nm using a microplate reader (BioRad, 197 
Model 680, USA). Nitric oxide (NO) production was calculated as percentage of control. All samples were 198 
analyzed in quadruplicate. 199 
 200 
2.10. Cell viability 201 
Cell viability determination was performed using the MTT assay according to the method of Phosri et al. [11]. 202 
RAW 264.7 cells (1 × 105 cells/mL) were cultured on a 96-well plate overnight. Lipopolysaccharides (LPS) 203 
were co-incubated with CHHs in defined concentrations (62, 125, 250 and 500 µg/mL) and 100 ng/mL of LPS 204 
at 37 C in a 5% CO2 humidified atmosphere. After incubation for 24 H the medium was discarded. MTT (3-205 
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (0.5 mg/mL) was added to RAW 264.7 cells and 206 
incubated at 37 C in a 5% CO2 humidified atmosphere for 30 min before the medium was discarded. DMSO 207 
was added and the reaction mixture incubated at 25 C for 30 min. The absorbance was measured at 570 nm and 208 
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the cell viability evaluated by comparing the absorbance with that of the control for each sample. All samples 209 
were analyzed in quadruplicate. 210 
 211 
2.11. Measurement of IL-6, IL-1β and PGE2 212 
Aliquots of culture medium employed in the NO assay were further used for determination of IL-6, IL-1β and 213 
PGE2 expression using the ELISA kit and following the instructions in the manufacturer’s manual (R&D, 214 
Minneapolis, MN, USA). 215 
 216 
2.12. Peptide purification from crocodile hemoglobin hydrolysates 217 
The purification of CHH was performed according to the method of Srihongthong et al. [9] with modifications. 218 
A HPLC system connected to a C-18 reverse phase column (10 × 150 mm; SunfireTm prep 5 µm) was employed 219 
in the purification process. Fractions were separated using a mobile phase system consisting of mobile phase A 220 
(0.1% TFA in deionized water) and mobile phase B (60% acetonitrile in 0.1% TFA) with a flow rate of 1.0 mL/ 221 
min. A gradient of 0-25% (v/v) B over 15 min, then 25-100% (v/v) B over 95 min was applied. The elution 222 
peaks were collected by monitoring the absorption at 220 nm. The antioxidant and anti-inflammatory activity of 223 
all peaks were assayed, followed by determination of the amino acid sequences for each peak showing 224 
significant biological activity. 225 
 226 
2.13. Amino acid sequence analysis 227 
The active fractions P16 of 2H-CHH and P57 of 6H-CHH were selected and the peptides identified using LTQ 228 
orbitrap XL Mass spectrometry employing the following search parameters: non-specified enzymatic cleavage 229 
with three possible missed cleavages, +/−0.8 Da mass tolerances for MS and MS/MS, a peptide mass tolerance 230 
of +/−5 ppm, methionine oxidation and Gln‐>pyro‐Glu (N‐term Q) variable modification, and monoisotopic 231 
mass. Data were additionally processed at the Mascot Server (http://www.matrixscience.com/) using MS/MS 232 
ion searches against SwissProt (current release). 233 
 234 
2.14. In vitro simulated gastric and intestinal digestion  235 
In vitro digestion models were used to simulate the condition of human stomach and intestine for observing 236 
remaining activity of CHHs as described by Cheong et al. [26] with modification. The ratio of sample: simulated 237 
gastric: simulated intestinal was 1: 1.5: 2. Simulated gastric solution was prepared by dissolving 2 g of NaCl, 7 238 
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mL of HCl and 3.2 g pepsin with DI up to 1 L. The pH was adjusted to 1.6 using 1 M HCl and maintained at 37 239 
C in a temperature-controlled water bath (Julabo, Germany). Each CHHs were mixed and pH was adjusted to 240 
2.5 using 1 M HCl then incubated at 37 C for 1 H. The simulated intestinal solution was prepared by mixing 241 
160 mL bile salts solution (5 mg/mL in PBS), 100 mL of pancreatin solution (4.8 mg/mL in PBS) and 40 mL of 242 
CaCl2 solution (110 mg/mL in PBS). The pH was adjusted to 7 and maintained at 37 C in a temperature-243 
controlled water bath. After the gastric digestion, samples were immediately adjusted to pH 7 with 1 M NaOH. 244 
Digested samples were added to simulated intestinal solution and incubated at 37 C for 2 H. Samples were 245 
adjusted to pH 9 to ensure enzyme inactivation. 246 
 247 
2.15. Hemolytic activity 248 
The hemolytic activity was determined according to the method of Pata et al. [27]. After isolation of the 249 
erythrocytes by centrifugation at 1,000g for 5 min, human red blood cells (hRBCs) were washed three times 250 
with PBS, pH 7.4 and then adjusted to 2% (v/v). Ten microliter CHHs were added separately to the 100 μL 251 
reaction solution, incubated for 1 H at 37 C and centrifuged at 1,000g for 5 min. 100 μL of supernatant was 252 
then transferred into 96-well plate. The absorbance was measured at 415 nm. 1% (v/v) Triton X-100 and DI 253 
used as positive and negative control respectively. All samples were analyzed in quadruplicate. 254 
 255 
2.16. Statistical analysis 256 
Statistical analysis was performed using ANOVA and followed by Dunnett’s test (Prism 5.0, GraphPad Inc., San 257 
Diego, CA, USA). Data are presented as mean ± SEM. A value of P < 0.05 was accepted to be significant (*P < 258 
0.05, ** P < 0.01, ***P < 0.001). 259 
 260 
3. Results and Discussion  261 
3.1. Preparation of crocodile hemoglobin hydrolysates (CHHs) and degree of hydrolysis (DH) 262 
In the present study, crocodile (C. siamensis) hemoglobin was extracted from red blood cells. To obtain active 263 
fragments, crocodile hemoglobin was hydrolyzed by pepsin digestion at different reaction times. The extent of 264 
enzymatic protein degradation was evaluated by degree of hydrolysis (DH) which was 20.4%, 23.1%, 25.0% 265 
and 35.9% for 2 H, 4 H, 6 H and 8 H of incubation, respectively (Fig. 1). Results indicated that cleavage of 266 
peptide bonds was higher in longer enzymatic hydrolysis. 267 
 268 
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3.2. Antioxidant activity, purification and amino acid sequence identification of CHHs 269 
NO is a very unstable radical which produces highly reactive molecules [28]. Intact crocodile Hb and all 270 
investigated Hb hydrolysates inhibited NO radicals (Fig. 2a). Notably, the hydrolysates had superior antioxidant 271 
activity compared to intact Hb at all concentrations (15-500 µg/mL). The NO-scavenging activity of the intact 272 
protein (500 µg/mL) was 75.7%, while the inhibitory ability of the hydrolysates, including 2H-CHH, 4H-CHH, 273 
6H-CHH and 8H-CHH, showed inhibition percentages of 77.4%, 78.2%, 88.3% and 83.1%, respectively. 274 
Moreover, BHT employed as positive standard displayed 77.8% NO radical inhibition. These results indicate 275 
that CHHs obtained by pepsin digestion possess pronounced antioxidant activity against nitric oxide radicals. 276 
From the report of Kabbua et al. [29] found that recombinant α-globin from cHb can act as a heme-nitric oxide 277 
and/or oxygen binding (H-NOX) hemoprotein. Furthermore, the value of NO inhibition activity of CHH was 278 
higher than yellowﬁn tuna hydrolysate [30]. 279 
Lipid peroxidation is considered to be a free radical process involving a source of secondary free radical, which 280 
can act as secondary messenger or directly react with other biomolecules, enhancing biochemical lesions. The 281 
results of linoleic peroxidation assay reveal that 2H-CHH, 4H-CHH, 6H-CHH and 8H-CHH (at concentrations 282 
of 0.005-500 µg/mL) effected significant inhibition of linoleic peroxidation in a concentration dependent 283 
manner when compared with Trolox. The inhibitory ability of all hydrolysates, including 2H-CHH, 4H-CHH, 284 
6H-CHH and 8H-CHH were 94.2%, 79.0%, 97.0% and 82.2%, respectively. Moreover, Trolox (500 µg/mL) 285 
showed 94.4% of linoleic peroxidation inhibition and intact Hb showed 89.1% inhibition (Fig. 2b). Furthermore, 286 
the linoleic peroxidation inhibition of protein hydrolysates obtained from smooth hound has been investigated. 287 
As shown by the results, the value of this activity was lower than that obtained in this study [31]. 288 
2H-CHH, 4H-CHh, 6H-CHH and 8H-CHH at the highest concentration (500 µg/mL) displayed significant ferric 289 
ion reducing power. 4H-CHH displayed the highest reduction activity equivalent to Trolox of about 2.1 mM, 290 
while intact Hb, 2H-CHH, 6H-CHH and 8H-CHH displayed reduction equivalents of 0.8, 1.2, 1.4 and 0.6 mM 291 
Trolox (Fig. 2c). Moreover, 500 µg/mL glutathione (positive control) affected significant ferric ion reduction 292 
equivalent to Trolox at 18.60 mM (data not shown). It has been reported that hydrolysates with high reducing 293 
power show a great ability to donate electrons to form stable compounds and thereby interrupt the free radical 294 
chain reactions and showing antioxidant activity [32]. 295 
Due to displaying the highest antioxidant activity in prior experiments, 6H-CHH was subjected to purification 296 
by reverse phase C-18 column semi-preparative HPLC to identify the contained active peptide components. As 297 
shown in Fig. 3a, 61 individual fractions were eluted. All elution peaks were normalized to a concentration of 78 298 
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µg/mL and screened with respect to antioxidant activity by nitric oxide scavenging assay. After the activity 299 
screening, several active fragments including P2, P39, P40, P43, P45, P46 and P57 were associated with nitric 300 
oxide radical inhibition rates of 19.5%, 21.2%, 17.3%, 16.1%, 18.7%, 18.1% and 32.0%, respectively. The 301 
highest activity in inhibiting nitric oxide radicals was found for P57 (32.0%), while the positive control (BHT) 302 
showed 68.1% nitric oxide radical inhibition (Fig. 3b).       303 
The primary structures of the purified antioxidant peptides were elucidated using LTQ orbitrap XL mass 304 
spectrometry (Fig. 4). Amino acid sequence of P57 was KIYFPHF (KF7) with molecular mass of 476.26 Da. As 305 
shown in Table 1, antioxidant peptide KF7 showed 42% hydrophobicity and a +1 net charge. Alignment of the 306 
amino acid sequences of the peptide fragments with cHb indicated the antioxidant peptides originated from the 307 
α-subunit, this observation is in excellent agreement with results of Srihongthong et al. [9], who reported that 308 
the α-subunit of cHb exhibited higher antioxidant activity than the β-subunit. Peptide fractions from acid-309 
digested cHb with a molecular mass of 180 to 3,000 Da are reported to exhibit antioxidant activity [33]. 310 
Notably, mass spectrometric analysis further revealed an apparent correlation of peptide length with biological 311 
activity as antioxidant peptides were found to be smaller and shorter molecules. In a previous study, Peña-312 
Ramos et al. [34] reported that the presence of particular amino acids including His, Tyr, Met, Lys, Trp and Pro 313 
correlates with increased antioxidant potency of most food-derived peptides. Likewise, the presence of Leu, Ile, 314 
His, Met, Tyr, Lys and Trp is assumed to contribute to the reducing power of protein hydrolysates [35]. In 315 
addition, peptides containing His residues have been documented to exhibit protective effects against lipid 316 
peroxidation. An imidazole ring of His has been implicated in the donation of hydrogen and trapping of lipid 317 
radicals [36]. Trp, Tyr and Met exhibited the highest antioxidant properties, followed by Phe, Cys and His [37]. 318 
Nitric oxide, however, is also scavenged by CHH, presumably due to the presence of reactive thiol groups [38]. 319 
 320 
3.3. Anti-inflammatory activity, purification and amino acid sequences identification of CHHs  321 
The anti-inflammatory property of intact Hb and CHHs was evaluated on the basis of NO production and cell 322 
viability against macrophage RAW 264.7 cells (Fig. 5). After induction of inflammation in RAW 264.7 cells by 323 
LPS for 24 H, the percentage of nitric oxide production was defined as 100% when treated with LPS. Fig. 5a, 324 
2H-CHH, 4H-CHH, 6H-CHH and 8H-CHH (at concentrations of 62-500 µg/mL) show nitric oxide production 325 
decrease in a concentration dependent manner. Intact Hb, 2H-CHH, 4H-CHH, 6H-CHH and 8H-CHH at a 326 
concentration of 500 µg/mL show nitric oxide production at 56.5%, 52.6%, 68.6%, 62.0% and 60.9%, 327 
respectively. In order to evaluate potential cytotoxic effects of CHHs, the viability of RAW 264.7 cells treated 328 
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with defined concentrations of CHHs was determined (Fig. 5b). The results showed that intact Hb, 2H-CHH, 329 
4H-CHH, 6H-CHH and 8H-CHH at concentrations of 62-500 µg/mL had no observable effect on cell viability 330 
while the viability percentage of cells treated with LPS only was defined as 100%. This result indicates that 331 
CHHs show high efficacy to reduce nitric oxide production and are essentially non-toxic to macrophage RAW 332 
264.7 cells, these results correlate with that from the report of Phosri et al. [11] who reported that cHb provides 333 
anti-inflammatory activity via the suppression of nitric oxide synthase (NOS), which inhibits the NO 334 
production. Jangpromma et al. [39] reported that cHb significantly decreased the production of NO in LPS-335 
stimulated RAW 264.7 cells and decreased inducible nitric oxide synthase (iNOS). In addition, results showed 336 
that CHHs have higher anti-inflammatory activity than gastropod (Harpa ventricosa) hydrolysate [40].  337 
Since 2H-CHH was found to possess the highest anti-inflammatory activity, its peptide constituents were 338 
purified by reverse phase C-18 column semi-preparative HPLC. The resulting chromatogram depicted in Fig. 6a 339 
consists of 59 fraction peaks which were diluted to a concentration of 31 µg/mL prior to anti-inflammatory 340 
activity determination. The assay revealed 6 peaks (P16, P17, P28, P29, P30 and P38) which show nitric oxide 341 
production at 83.2%, 86.0%, 87.9%, 88.8%, 86.3% and 83.6% (Fig. 6b) with no effect on the viability of RAW 342 
264.7 cells (Fig. 6c). Moreover, these fractions were also selected to determine the influence on the expression 343 
levels of IL 6, IL-1β and PGE2 (Table 2). The results indicate that P16, P17, P28, P29, P30 and P38 are able to 344 
significantly decrease IL-6 and PGE2 production, whereas P16 and P17 further inhibited IL-1β production. 345 
Notably, P16 showed the highest activity to decrease IL-6 levels (approximately 2.0 ng/mL) compared to LPS 346 
and effectively decreased the IL-1β level to about 0.3 ng/mL. P16 showed the highest activity to reduce PGE2 347 
levels (approximately 1.9 ng/mL) when compared to LPS. Furthermore, P16 was found to reduce the production 348 
of pro-inflammatory cytokines and inflammatory mediators IL-6, IL-1β and PGE2, which are associated with the 349 
inflammation-related in neuropathological diseases, for example Alzheimer’s, multiple sclerosis and cerebral 350 
ischemia [41, 42]. IL-6 that acts as a multifunctional cytokine was up-regulated by lipopolysaccharide (LPS). In 351 
inflammation, trauma and autoimmune diseases were found high expression levels of IL-1β and IL-6 [43]. 352 
Furthermore, IL-1β induced IL-6 production is mediated predominantly through the p38 MAPK/NF-κB 353 
pathway [44]. cHb was found to exhibit anti-inflammatory effects in the cotton pellet model and RAW 264.7 354 
cells by reducing expression levels of IL-1β, TNF-α, COX-2 and IL-6 mRNA [39, 45]. The collected results in 355 
this work indicate that the anti-inflammatory activity of sample might be related to an interaction with the 356 
MAPK/NF-κB pathway by their ability to decrease pro-inflammatory cytokine and inflammatory mediator 357 
production. 358 
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The primary structures of the purified anti-inflammatory peptides were elucidated using LTQ orbitrap XL mass 359 
spectrometry (Fig. 4). Amino acid sequences of P16 were determined as SAFNPHEKQ (SQ9) and 360 
IIHNEKVQAHGKKVL (IL15) corresponding to molecular mass of 529.26 Da and 857.51 Da, respectively. As 361 
shown in Table 1, anti-inflammatory peptides SQ9 and IL15 had hydrophobicity values of about 22% and 40%, 362 
together with net charges of 0 and +2, respectively. The sequence of the anti-inflammatory peptide showed 363 
strong correlation with the β-chain of cHb. Likewise, the anti-inflammatory activity of SQ9 and IL15 was traced 364 
back to the presence of specific amino acids. According to reports, anti-inflammatory peptides can be found in a 365 
wide molecular weight range [20, 46]. Hydrophobic amino acid side chains (e.g. Leu, Phe, Val, Ile, and Trp) as 366 
well as positively charged amino acids (Lys, Arg and His) were documented to have a major influence on the 367 
anti-inflammatory activity of peptides [47-52].  368 
 369 
3.4. In vitro simulated gastric and intestinal digestion of CHHs and its activity  370 
Simulated gastric and intestinal digestion (in vitro digestion model) was used as the conditions of human 371 
stomach and intestine. The degree of hydrolysis of 2H-CHH and 6H-CHH after intestinal digestion was 372 
increased about 3.7% and 8.8%, respectively. From the results, it is inferred that CHH tended to be more 373 
hydrolyzed by intestinal digestion. Gastrointestinal tract is known to be a major oxidation site where various 374 
free radicals are generated in the digestion process [53]. As shown in Fig. 7a, 6H-CHH after intestinal digestion 375 
was inhibited nitric oxide (42.5%, the concentration of 125 µg/mL) and exhibited higher reducing power (2.8 376 
mM Trolox equivalent, the concentration of 500 µg/mL) than 6H-CHH before intestinal digestion (Fig. 7b). 377 
With excellent agreement with Moure et al. [36] who reported that the reducing power increased with higher 378 
degree of hydrolysis. The anti-inflammatory activity of 2H-CHH after intestinal digestion showed NO 379 
production (19.8%, the concentration of 125 µg/mL) without toxicity against macrophage RAW 264.7 cells 380 
(Figs. 8a and 8b). During the course of the inflammation high amounts of free radicals are produced within the 381 
inflamed tissue, in particular NO, which acts as a major pro-inflammatory mediator in the human body and is 382 
generated from macrophage in response to the inflammation [8]. In this context, NO is generally regarded as the 383 
key mediator correlating inflammation and oxidative stress. The capability of NO production has decreased 384 
resulting in the reduction of detrimental effects of both inflammation and oxidative damage. The hemolytic 385 
activity was performed to determine the toxicity against human red blood cells and the results showed that both 386 
2H-CHH and 6H-CHH at all concentrations were not toxic against human red blood cells (Figs. 9a and 9b). So 387 
far, only a few bioactive peptides including peptides in this study displaying activities in vitro that have been 388 
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proven effective in vivo. Results indicated that both 2H-CHH and 6H-CHH with intestinal digestion have 389 
potential to be used as an alternative source of antioxidant and anti-inflammatory agents with safety.  390 
 391 
4. Conclusions 392 
A number of novel antioxidant and anti-inflammatory peptides were derived from pepsin hydrolysis of cHb. 393 
Experimental evidence collected in this study indicates the antioxidant fragment is a comparatively small 394 
peptide, consisting of only 7 amino acid residues with slightly positive charge and low hydrophobicity. 395 
Similarly, the peptides with anti-inflammatory activity were found to comprise 9 and 15 amino acid residues, 396 
respectively, and are also characterized by positive charge and low hydrophobicity. This is the first report to 397 
identify antioxidant and anti-inflammatory peptides from pepsin digested cHb. Due to their remarkable 398 
biological activity, ease of production and absence of cytotoxicity, these naturally-derived peptides are believed 399 
to bear a great potential for a future application as health promoting supplements and therapeutic agents against 400 
inflammation and oxidative stress-related conditions.      401 
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*denotes P < 0.05 and *** denotes P < 0.001. Data expressed as a mean ± SEM of 3 independent experiments. 522 
Significance was measured using ANOVA followed by Dunnett’s test.  523 
 524 
 525 
 526 
 527 
 528 
TABLE 1  Structural characteristics of the anti-inflammatory peptides (P16) from 2H-CHH and      
antioxidant peptide (P57) from 6H-CHH 
Properties Peptide sequences Hydrolysates 
% hydropho-
bicity 
Net 
charge 
Sequence alignment 
Anti-
inflammatory 
SAFNPHEKQ (SQ9) 2H-CHH 22%   0 
 
cHb β-subunit  
(position 2-10) 
 
Anti-
inflammatory 
IIHNEKVQAHGKKVL 
(IL15) 
2H-CHH 40% +2 
cHb β-subunit 
(position 55-69) 
 
Antioxidant KIYFPHF (KF7) 6H-CHH 42% +1 
cHb α-subunit 
(position 41-47) 
 
 
TABLE 2  
 
IL-6, IL-1β and PGE2 production in LPS-stimulated RAW 264.7 cells 
incubated with purified fractions of 2H-CHH at a concentration of 31 
µg/mL 
 
Fraction peaks (P) 
The production concentration (ng/mL) 
IL-6 IL-1β PGE2 
LPS 10.647 ± 0.213 0.360 ± 0.002 6.486 ± 0.163 
P16 2.019*** ± 0.000 0.315*** ± 0.002 1.871*** ± 0.068 
P17 7.287*** ± 0.447 0.338 ± 0.001 1.877*** ± 0.042 
P28 7.967*** ± 0.110 0.420*** ± 0.002 3.046*** ± 0.220 
P29 9.340* ± 0.155 0.412*** ± 0.001 3.578*** ± 0.035 
P30 9.407* ± 0.116 0.430*** ± 0.002 2.880*** ± 0.205 
P38 4.707*** ± 0.173 0.538*** ± 0.011 3.181*** ± 0.377 
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Figure captions 529 
 530 
FIG. 1  Degree of hydrolysis (% DH) of CHH after pepsin digestion for 2, 4, 6 and 8 H. Hemoglobin 531 
hydrolyzed enzymatically by pepsin displayed a direct correlation between the rate of hydrolysis (DH) 532 
and the time of incubation (H). 533 
 534 
FIG. 2  (a) Nitric oxide scavenging activity of CHHs at concentrations of 15-500 µg/mL. Each bar displays the 535 
mean ± SEM of four demonstrations. (** P < 0.01 and *** P < 0.001) probability levels compared 536 
with BHT. (b) Linoleic peroxidation activity of CHHs at concentration of 0.005-500 µg/mL. Each bar 537 
displays the mean ± SEM of six demonstrations. (* P < 0.05, ** P < 0.01 and *** P < 0.001) 538 
probability levels compared with Trolox and (c) reducing power of CHHs at concentration of 0.005-539 
500 µg/mL expressed in Trolox equivalents. Each bar displays the mean ± SEM of four demonstrations. 540 
(***P < 0.001) probability levels compared with glutathione.  541 
 542 
FIG. 3  Reverse phase C-18 column semi-preparative HPLC profile of (a) 6H-CHH. 0.1% Trifluoroacetic acid 543 
(TFA) in deionized water and 60% acetonitrile in 0.1% Trifluoroacetic acid (TFA) were chosen as 544 
mobile phase A and B, respectively. CHH was filtered through 25 mm PES filters and 700 µg (4 mL) 545 
were injected at 1.0 mL/ min of flow rate. The linear gradient was 0-25% (v/v) mobile phase B over 15 546 
min, then 25-100% (v/v) mobile phase B over 95 min. (b) The antioxidant activity of purified peaks 547 
from 6H-CHH (78 µg/mL) determined by the nitric oxide scavenging assay. Each bar displays the 548 
mean ± SEM of four demonstrations (*** P < 0.001).   549 
 550 
FIG. 4  Mass spectrogram of anti-inflammatory peptides and antioxidant peptide from P16 (2H-CHH) and P57 551 
(6H-CHH), respectively, determined by LTQ orbitrap XL mass spectrometry. The following sequence 552 
interpretation was concluded: anti-inflammatory peptides were identified as (a) Ser-Ala-Phe-Asn-Pro-553 
His-Glu-Lys-Gln (SAFNPHEKQ) and (b) Ile-Ile-His-Asn-Glu-Lys-Val-Gln-Ala-His-Gly-Lys-Lys-Val-554 
Leu (IIHNEKVQAHGKKVL) and (c) the antioxidant peptide was identified as Lys-Ile-Tyr-Phe-Pro-555 
His-Phe (KIYFPHF). 556 
 557 
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FIG. 5  The effect of CHHs on (a) NO production in LPS-activated macrophage RAW 264.7 cells and (b) the 558 
cytotoxicity (cell viability) of CHHs on macrophage RAW 264.7 cells determined by the MTT assay. 559 
CHHs (62-500 µg/mL) were then incubated with macrophage RAW 264.7 cells and another overnight 560 
incubation was set between LPS and macrophage RAW 264.7 cells. The media were further used to 561 
measure the nitrite level (NO assay). Each bar displays the mean ± SEM of four demonstrations (* P < 562 
0.05, ** P < 0.01 and *** P < 0.001).   563 
 564 
FIG. 6   Reverse phase C-18 column semi-preparative HPLC profile of (a) 2H-CHH. 0.1% Trifluoroacetic acid 565 
(TFA) in deionized water and 60% acetonitrile in 0.1% Trifluoroacetic acid (TFA) were chosen as 566 
mobile phase A and B, respectively. CHH was filtered through 25 mm PES filters and 700 µg (4 mL) 567 
were injected at 1.0 mL/ min of flow rate. The linear gradient was 0-25% (v/v) mobile phase B over 15 568 
min, then 25-100% (v/v) mobile phase B over 95 min. (b) The anti-inflammatory property of purified 569 
peaks from 2H-CHH (31 µg/mL) against NO production determined in LPS-activated macrophage 570 
RAW 264.7 cells. (c) The cytotoxicity (cell viability) of purified peaks from 2H-CHH (31 µg/mL) on 571 
macrophage RAW 264.7 cells determined by the MTT assay. Each bar displays the mean ± SEM of four 572 
demonstrations (* P < 0.05, ** P < 0.01 and *** P < 0.001).   573 
 574 
FIG. 7  (a) Nitric oxide scavenging activity of 6H-CHHs after intestinal digestion at concentrations of 15-125 575 
µg/ mL. Each bar displays the mean ± SEM of four demonstrations. (* P < 0.05 and *** P < 0.001) 576 
probability levels compared with BHT. (b) Reducing power at concentration of 0.005-500 µg/mL 577 
expressed in Trolox equivalents. Each bar displays the mean ± SEM of four demonstrations. (***P < 578 
0.001) probability levels compared with glutathione. 579 
 580 
FIG. 8  The effect of 2H-CHHs after intestinal digestion on (a) NO production in LPS-activated macrophage 581 
RAW 264.7 cells and (b) the cytotoxicity (cell viability) on macrophage RAW 264.7 cells determined by 582 
the MTT assay. 2H-CHHs (31-125 µg/mL) were then incubated with macrophage RAW 264.7 cells and 583 
another overnight incubation was set between LPS and macrophage RAW 264.7 cells. The media were 584 
further used to measure the nitrite level (NO assay). Each bar displays the mean ± SEM of four 585 
demonstrations (* P < 0.05, ** P < 0.01 and *** P < 0.001).   586 
 587 
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FIG. 9  The hemolytic activity of (a) 2H-CHH after intestinal digestion and (b) 6H-CHH after intestinal 588 
digestion against human red blood cells. Each bar displays the mean ± SEM of four demonstrations 589 
(*** P < 0.001).   590 
 591 
 592 
